Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 576 - 600 of 14399 in total
Bumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic, and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis and gout . Its use is restricted to these conditions, due to risks this drug poses .
Approved
Matched Description: … , and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis and gout ... Bumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic …
Matched Categories: … Acetic Acid Derivatives and Related Substances ... Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclinical and clinical trials....
Approved
Investigational
Matched Description: … agonists in preclinical and clinical trials. ... only GIP and GLP-1 receptor agonist for this indication. ... Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
An imidazole antithyroid agent. Carbimazole is metabolized to methimazole, which is responsible for the antithyroid activity.
Approved
Investigational
Matched Categories: … Sex Hormones and Insulins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)
Approved
Matched Description: … It is used in musculoskeletal and joint disorders and administered by mouth and topically. ... An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Factor XIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation cascade [FDA Label]. For people with congenital deficiency or mutation of Factor XIII, a rare bleeding disorder, exogenous replacement of this key...
Approved
Investigational
Matched Description: … and maintenance of hemostasis [A18581]. ... in adult and pediatric patients with congenital FXIII deficiency [FDA Label]. ... in increased mechanical strength and resistance to fibrinolysis of the fibrin clot. …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Nonacog beta pegol is a recombinant coagulation factor IX derivative. It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) molecule for peptide activation by a site-directed glycoPEGylation. Once activated, the activation molecule with PEG is cleaved to leave the activated factor IX (Factor IXa). Nonacog...
Approved
Investigational
Matched Description: … It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) ... [A31496] Nonacog beta pegol was developed by Novo Nordisk and received its first global approval by the …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets.
Approved
Matched Categories: … Alimentary Tract and Metabolism …
Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain,...
Approved
Matched Description: … soft tissue pain, and ankylosing spondylitis. ... tablet, injectable, nasal spray and as an ophthalmic solution. ... Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral …
Matched Categories: … Mydriatics and Cycloplegics ... phenylephrine and ketorolac ... Acetic Acid Derivatives and Related Substances ... Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome...
Approved
Investigational
Matched Description: … Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old. ... Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein ... Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets . The U.S. Food and Drug Administration approved Crysvita (burosumab) in April 2018. This is the first drug approved...
Approved
Investigational
Matched Description: … It causes impaired bone growth and development in children and adolescents and issues with bone mineralization ... This is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia ... Food and Drug Administration approved Crysvita (burosumab) in April 2018. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs Affecting Bone Structure and Mineralization …
A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss.
Approved
Matched Description: … It also tends to lower blood pressure and increase potassium loss. …
Matched Categories: … Genito Urinary System and Sex Hormones ... metolazone and potassium-sparing agents ... Gynecological Antiinfectives and Antiseptics ... Low-Ceiling Diuretics and Potassium-Sparing Agents …
Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.[L7634,L7637,L7640,L7643,L8519] Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.[L7640,L7643] Glucagon was granted FDA...
Approved
Matched Description: … diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and ... Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and
Matched Categories: … Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin. ESA is used to increase synthesis of red blood cells to treat chronic kidney disease associated anemia.
Approved
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …
Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis...
Approved
Withdrawn
Matched Description: … the chronic complications such as chronic active hepatitis and cirrhosis. ... epidemiology vary widely among geographical areas and population subgroups. ... Other causative agents are hepatitis A virus, and the non-A, non-B hepatitis viruses. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Bacterial and viral vaccines, combined ... haemophilus influenzae B and hepatitis B …
Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.
Approved
Withdrawn
Matched Categories: … Acetic Acid Derivatives and Related Substances ... Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Ascorbyl phosphate is a synthetic form of Vitamin C and is found in different salt forms such as magnesium ascorbyl phosphate and sodium ascorbyl phosphate. These salts are present in cosmetic products at concentrations ranging from 0.001 % to 3% . As vitamin C is susceptible to breakdown of compound...
Approved
Matched Description: … ascorbyl phosphate and sodium ascorbyl phosphate. ... Ascorbyl phosphate is a synthetic form of Vitamin C and is found in different salt forms such as magnesium ... phosphate, along with other Vitamin C derivatives, acts as an active and stable precursor of vitamin …
Matched Categories: … Vitamin C and analogues …
Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A). This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys,...
Approved
Investigational
Matched Description: … in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and ... L4274,L4278] In the U.S., it is estimated that more than 3,000 people are living with Fabry disease, and ... [L4274] Given the rarity of Fabry disease and the proportion of Fabry disease patients that could …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …
Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Approved
Matched Description: … Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic ... [A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class...
Approved
Investigational
Matched Description: … increase the number and sensitivity of insulin receptors. ... Renal and hepatic dysfunction may increase the risk of hypoglycemia. ... Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear,...
Approved
Investigational
Matched Description: … It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, ... mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and
Matched Categories: … Alimentary Tract and Metabolism ... Papaverine and Derivatives ... Genito Urinary System and Sex Hormones …
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to...
Approved
Investigational
Matched Description: … humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and ... [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn...
Approved
Investigational
Withdrawn
Matched Description: … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis. It inhibits the actions of interleukin-23 (IL-23), a pro-inflammatory cytokine that activates pathways contributing to the development of inflammatory diseases.[L46237,L46257] Mirikizumab is approved in Japan and received a positive opinion from the EMA's Committee for Medicinal...
Approved
Investigational
Matched Description: … [L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and ... [L46237,L46257] Mirikizumab is approved in Japan[L46252] and received a positive opinion from the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Infection with pathogenic filoviruses, such as Zaire ebolavirus (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as 90%.[A225933, A225938] Virtually all steps of the EBOV lifecycle have been targeted for therapeutic development. However, to date, the most successful...
Approved
Investigational
Matched Description: … to be superior, with improved patient survival and faster viral clearance rates. ... [maftivimab]), the now approved ansuvimab, and ZMapp, which remains in clinical trials. ... evidenced by the previously approved INMAZEBâ„¢ (REGN-EB3, a cocktail of [atoltivimab], [odesivimab], and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase, and aldehyde oxidase. Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity.[A230088,L32163]...
Approved
Matched Description: … [A230088] Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites ... paraplegia, myoclonus, and opisthotonus. ... a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase, and
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …
Displaying drugs 576 - 600 of 14399 in total